Tilactase - Pro Farma

Drug Profile

Tilactase - Pro Farma

Alternative Names: Lacdigest

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Pro Farma
  • Developer MN Pharmaceuticals; Recordati
  • Class Galactosidases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Lactose intolerance

Most Recent Events

  • 10 Jul 2009 Launched for Lactose intolerance in Turkey (PO) after July 2009
  • 10 Jun 2009 Registered for Lactose intolerance in Turkey (PO) (MN Pharmaceuticals website, August 2016)
  • 31 Mar 2009 Launched for Lactose intolerance in Italy (PO) after March 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top